{"title":"血浆溶血磷脂酸和CD62P对缺血性脑卒中预后的预测价值。","authors":"Sabeeha Naaz, Swarna Anupama, Thrilok Chander Bingi","doi":"10.4103/aian.aian_83_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Stroke is the second leading cause of death worldwide, and only 10% of the patients can live their normal lives. As per the Global Burden of Disease Study 2016, the incidence of stroke in India is reported to be 1,175,778 (1 076 048 to 1,274,427) per 100000 person-years. A novel biochemical marker that can predict the stroke outcome can reduce morbidity, especially when thrombolysis cannot be done. Hence, the current study aims to study the role of plasma lysophosphatidic acid (LPA) and CD62P as prognostic markers for acute ischemic stroke.</p><p><strong>Methods: </strong>This is a prospective observational study. Ninety-six patients who met the inclusion criteria were enrolled. The plasma LPA and CD62P levels were estimated using the enzyme-linked immunosorbent assay and correlated with the Alberta stroke program early computed tomography score (ASPECTS) on CT brain and modified Rankin scale (mRS) at 90 days.</p><p><strong>Results: </strong>Age, sex, and other risk factors in the ischemic stroke patients did not have any impact on the levels of LPA and CD62P. Both LPA (P = 0.000) and CD62P (P = 0.005) showed a positive correlation with mRS after 90 days. The mean LPA was highest for mRS 5 and least for mRS 1, whereas the mean CD62P levels did not correlate with increasing mRS. The ASPECTS showed a significant negative correlation only with LPA.</p><p><strong>Conclusions: </strong>High LPS and CD62P levels after stroke onset tend to be associated with poor mRS scores at 90 days.</p>","PeriodicalId":8036,"journal":{"name":"Annals of Indian Academy of Neurology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of Plasma Lysophosphatidic Acid and CD62P in the Outcome of Ischemic Stroke.\",\"authors\":\"Sabeeha Naaz, Swarna Anupama, Thrilok Chander Bingi\",\"doi\":\"10.4103/aian.aian_83_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Stroke is the second leading cause of death worldwide, and only 10% of the patients can live their normal lives. As per the Global Burden of Disease Study 2016, the incidence of stroke in India is reported to be 1,175,778 (1 076 048 to 1,274,427) per 100000 person-years. A novel biochemical marker that can predict the stroke outcome can reduce morbidity, especially when thrombolysis cannot be done. Hence, the current study aims to study the role of plasma lysophosphatidic acid (LPA) and CD62P as prognostic markers for acute ischemic stroke.</p><p><strong>Methods: </strong>This is a prospective observational study. Ninety-six patients who met the inclusion criteria were enrolled. The plasma LPA and CD62P levels were estimated using the enzyme-linked immunosorbent assay and correlated with the Alberta stroke program early computed tomography score (ASPECTS) on CT brain and modified Rankin scale (mRS) at 90 days.</p><p><strong>Results: </strong>Age, sex, and other risk factors in the ischemic stroke patients did not have any impact on the levels of LPA and CD62P. Both LPA (P = 0.000) and CD62P (P = 0.005) showed a positive correlation with mRS after 90 days. The mean LPA was highest for mRS 5 and least for mRS 1, whereas the mean CD62P levels did not correlate with increasing mRS. The ASPECTS showed a significant negative correlation only with LPA.</p><p><strong>Conclusions: </strong>High LPS and CD62P levels after stroke onset tend to be associated with poor mRS scores at 90 days.</p>\",\"PeriodicalId\":8036,\"journal\":{\"name\":\"Annals of Indian Academy of Neurology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Indian Academy of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/aian.aian_83_25\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Indian Academy of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/aian.aian_83_25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Prognostic Value of Plasma Lysophosphatidic Acid and CD62P in the Outcome of Ischemic Stroke.
Background and objectives: Stroke is the second leading cause of death worldwide, and only 10% of the patients can live their normal lives. As per the Global Burden of Disease Study 2016, the incidence of stroke in India is reported to be 1,175,778 (1 076 048 to 1,274,427) per 100000 person-years. A novel biochemical marker that can predict the stroke outcome can reduce morbidity, especially when thrombolysis cannot be done. Hence, the current study aims to study the role of plasma lysophosphatidic acid (LPA) and CD62P as prognostic markers for acute ischemic stroke.
Methods: This is a prospective observational study. Ninety-six patients who met the inclusion criteria were enrolled. The plasma LPA and CD62P levels were estimated using the enzyme-linked immunosorbent assay and correlated with the Alberta stroke program early computed tomography score (ASPECTS) on CT brain and modified Rankin scale (mRS) at 90 days.
Results: Age, sex, and other risk factors in the ischemic stroke patients did not have any impact on the levels of LPA and CD62P. Both LPA (P = 0.000) and CD62P (P = 0.005) showed a positive correlation with mRS after 90 days. The mean LPA was highest for mRS 5 and least for mRS 1, whereas the mean CD62P levels did not correlate with increasing mRS. The ASPECTS showed a significant negative correlation only with LPA.
Conclusions: High LPS and CD62P levels after stroke onset tend to be associated with poor mRS scores at 90 days.
期刊介绍：
The journal has a clinical foundation and has been utilized most by clinical neurologists for improving the practice of neurology. While the focus is on neurology in India, the journal publishes manuscripts of high value from all parts of the world. Journal publishes reviews of various types, original articles, short communications, interesting images and case reports. The journal respects the scientific submission of its authors and believes in following an expeditious double-blind peer review process and endeavors to complete the review process within scheduled time frame. A significant effort from the author and the journal perhaps enables to strike an equilibrium to meet the professional expectations of the peers in the world of scientific publication. AIAN believes in safeguarding the privacy rights of human subjects. In order to comply with it, the journal instructs all authors when uploading the manuscript to also add the ethical clearance (human/animals)/ informed consent of subject in the manuscript. This applies to the study/case report that involves animal/human subjects/human specimens e.g. extracted tooth part/soft tissue for biopsy/in vitro analysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
